Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb 1;108(5):2100-5.
doi: 10.1073/pnas.1014792108. Epub 2011 Jan 20.

Gastrin-releasing peptide blockade as a broad-spectrum anti-inflammatory therapy for asthma

Shutang Zhou  1 , Erin N Potts, Frank Cuttitta, W Michael Foster, Mary E Sunday
Affiliations

Gastrin-releasing peptide blockade as a broad-spectrum anti-inflammatory therapy for asthma

Shutang Zhou et al. Proc Natl Acad Sci U S A. .

Retraction in

  • Retraction.
    [No authors listed] [No authors listed] Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):E1813. doi: 10.1073/pnas.1504672112. Epub 2015 Mar 30. Proc Natl Acad Sci U S A. 2015. PMID: 25825774 Free PMC article. No abstract available.

Abstract

Gastrin-releasing peptide (GRP) is synthesized by pulmonary neuroendocrine cells in inflammatory lung diseases, such as bronchopulmonary dysplasia (BPD). Many BPD infants develop asthma, a serious disorder of intermittent airway obstruction. Despite extensive research, early mechanisms of asthma remain controversial. The incidence of asthma is growing, now affecting >300 million people worldwide. To test the hypothesis that GRP mediates asthma, we used two murine models: ozone exposure for air pollution-induced airway hyperreactivity (AHR), and ovalbumin (OVA)-induced allergic airway disease. BALB/c mice were given small molecule GRP blocking agent 77427, or GRP blocking antibody 2A11, before exposure to ozone or OVA challenge. In both models, GRP blockade abrogated AHR and bronchoalveolar lavage (BAL) macrophages and granulocytes, and decreased BAL cytokines implicated in asthma, including those typically derived from Th1 (e.g., IL-2, TNFα), Th2 (e.g., IL-5, IL-13), Th17 (IL-17), macrophages (e.g., MCP-1, IL-1), and neutrophils (KC = IL-8). Dexamethasone generally had smaller effects on all parameters. Macrophages, T cells, and neutrophils express GRP receptor (GRPR). GRP blockade diminished serine phosphorylation of GRPR with ozone or OVA. Thus, GRP mediates AHR and airway inflammation in mice, suggesting that GRP blockade is promising as a broad-spectrum therapeutic approach to treat and/or prevent asthma in humans.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: S.Z., E.N.P., W.M.F., and M.E.S. have submitted a patent application to the Duke Ventures office, but outside contacts have not yet been made.

Figures

Fig. 1.
Fig. 1.
GRP blockade abrogates O3-induced AHR and inflammation. (A and B) PFTs on BALB/C mice exposed to O3 or FA, using the flexiVent system. Mice given 77427 (A) or 2A11 (B) before O3 had decreased airway resistance at higher MCh doses (25 or 100 mg/mL). *P < 0.01, **P < 0.05, n = 8. (C and D) Pretreatment with 77427 (C) or 2A11(D) reduced numbers of BAL macrophages and PMN induced by O3.*P < 0.01, n = 8.
Fig. 2.
Fig. 2.
GRP blockade abrogates OVA-induced AHR and inflammation. (A and B) Pretreatment with 77427 (A) reduced airway resistance to MCh induced by OVA down to baseline. *P < 0.01, n = 8. (B) Treatment with 2A11 showed a similar pattern of responsiveness that was a statistical trend (0.10> P > 0.05). (C and D) OVA/OVA mice pretreated with 77427 (C) or 2A11 (D) had fewer BAL macrophages, PMN, and eosinophils. *P < 0.01, **P < 0.05, n = 8.
Fig. 3.
Fig. 3.
Lung histopathology and IHC in mouse lungs exposed OVA with or without GRP blockade. (A) Mice treated with OVA/OVA had inflammatory infiltrates with PMN, mononuclear cells, and eosinophils (short green arrows) throughout the airway epithelium (asterisks) and smooth muscle (long arrows) (H&E). (B) In contrast, OVA-immunized mice given 77427 before the first OVA aerosol challenge had rare inflammatory cells (green arrows) in airway epithelium (asterisks) or smooth muscle (long black arrows), except for perivascular infiltrates and a few cells outside airway smooth muscle (H&E). (C) GRP IHC in control mouse lungs treated with Alum/PBS/Saline. (D) GPR IHC of mouse lungs exposed to OVA/PBS/OVA, showing strong GRP signal in cells lining the alveolar ducts (black arrows). The same distribution of staining was observed for the general NE marker, PGP9.5. (E) In parallel to Fig. 3D, GRP IHC was performed by using anti-GRP antibody preabsorbed with excess GRP peptide. (Scale bars: 25 μm.) L, airway lumen; V, vascular lumen.
Fig. 4.
Fig. 4.
GRP blockade decreases O3- or OVA-induced BAL cytokine levels. Quantitative multiplex immunoassays show that GRP blockade by 77427 or 2A11 decreased O3- or OVA-induced BAL fluid cytokine levels, represented here by a Th1 cytokine, TNFα (A); a Th2 cytokine, IL-5 (B); a TH17 cytokine, IL-17 (C); and PMN-derived cytokine, KC (IL-8) (D). **P < 0.001, n = 5.
Fig. 5.
Fig. 5.
GRPR gene expression in macrophages, PMN, and T cells. Positive controls for QRT-PCR included normal 5-wk-old BALB/c lung (low positive levels) and small cell carcinoma cell line, H345 (high positive levels) (42).
Fig. 6.
Fig. 6.
GRP blockade decreases O3- or OVA-induced GRPR serine phosphorylation. (A) Immunoprecipitation and Western blot for pGRPR in mouse lungs exposed to O3 with or without 77427. One representative blot out of four total. (B) Similarly, GRPR serine phosphorylation in the OVA model. One representative blot out of four total. Statistical analysis of densitometry for Fig. 6 A and B is in Tables S3 and S4.
See this image and copyright information in PMC

Comment in

  • Findings of Research Misconduct.
    [No authors listed] [No authors listed] Fed Regist. 2019 Nov 7;84(216):60097-60098. Fed Regist. 2019. PMID: 37547121 Free PMC article. No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cotran RS, Kumar V, Collins T. Robbins' Pathologic Basis of Disease. 6th Ed. Philadelphia: Saunders; 1999.
    1. Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: Phenotype shaped by innate and adaptive immunity. Nat Immunol. 2010;11:577–584. - PMC - PubMed
    1. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol. 2002;109(5 Suppl):S482–S489. - PubMed
    1. Gaga M, et al. ENFUMOSA Study Group Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: An analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy. 2005;35:954–959. - PubMed
    1. Shore SA, Drazen JM. Beta-agonists and asthma: Too much of a good thing? J Clin Invest. 2003;112:495–497. - PMC - PubMed

Publication types

Substances